Linked Life Data

21753234

Source:http://linkedlifedata.com/resource/pubmed/id/21753234

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2011-7-20
pubmed:abstractText
Interstitial photodynamic therapy is becoming an interesting modality to treat some early stage prostate cancers. A light-sensitive drug is injected to the patient and activated by light using optical fibres inserted inside the prostate. In this work, we were interested in the characterization of the light action model for the WST11 (Tookad® Soluble) drug. A retrospective analysis was performed on results from 28 patients enrolled in phase I and II trials with the WST11 drug. A drug dose of 4 mg/kg patient, dose light of 200 J cm(-1) and wavelength of 753 nm were used. Correlation between the illuminated volume and the obtained necrosis, measured at day 7 MR images, was clearly established. This result suggests that photodynamic therapy planning is possible based on this model.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1361-6560
pubmed:author
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4771-83
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
pubmed:affiliation
Inserm U703, 152 rue du Docteur Yersin, 59120 Loos, France. Université Lille Nord de France, F-59000 Lille, France. CHU Lille, F-59000 Lille, France. n-betrouni@chru-lille.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't